Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis.

[1]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[2]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[3]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[4]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[5]  Geert Molenberghs,et al.  Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.

[6]  Harold I Feldman,et al.  Individual patient‐ versus group‐level data meta‐regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head , 2002, Statistics in medicine.

[7]  R. Temple.  Policy developments in regulatory approval , 2002, Statistics in medicine.

[8]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[9]  Stephanie Green,et al.  Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.

[10]  Daniel J Sargent,et al.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Michael Hughes.  The Evaluation of Surrogate Endpoints in Practice: Experience in HIV , 2005 .

[12]  Thomas R Fleming.  Objective response rate as a surrogate end point: a commentary. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Ahn,et al.  Comparison of RECIST and WHO response criteria in metastatic colorectal carcinoma , 2005 .

[14]  M. Sormani,et al.  Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Buyse,et al.  Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. , 2006, Pharmaceutical statistics.

[16]  Geert Molenberghs,et al.  Evaluation of Surrogate Endpoints , 2006, Handbook of Statistical Methods for Randomized Controlled Trials.

[17]  Marc Buyse,et al.  Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation , 2006, Pharmaceutical statistics.